Take your aesthetics business to the next level with this quick-start guide for introducing skin care lines to help boost your profits and enhance treatment results.
July 16, 2019
TEL: (888) 907-0115
Venus Concept is a leader in the global medical and aesthetic device market, pairing best-in-class technology with the first and only true subscription model in the industry.
As an experienced medical aesthetics practitioner, you are likely well aware of the difficulties in effectively treating stretch marks. However, growing demand in this area are making striae alba treatments a potential growth market worth exploring. Fortunately, advances in treatment technology have led to a radio frequency-based aesthetics device with proven results in treating troublesome stretch marks that could set your clinic apart from your top competitors.
According to recent reports, the global market for stretch mark reduction treatments is expected to grow at a compound annual growth rate of 7.7%, hitting an estimated overall market value of $4.0 billion by 2026. Further, an increased incidence rate of obesity globally, alongside increasing awareness surrounding the possibilities of non-invasive aesthetic treatments that complement a healthy, active lifestyle may further propel demand for stretch mark reduction treatments. The North American market is expected to dominate this area, with more than one-third of the estimated demand for stretch mark reduction treatments.
Further still, Medscape notes an estimated 90% of pregnant women, 70% of adolescent females, and 40% of adolescent males have developed stretch marks, though females are considered nearly three times more likely to develop them. Commonly appearing on the chest, abdomen, flanks, and buttocks, stretch marks can affect patients of any skin type or ethnic background.
For your patients, embarrassment regarding stretch marks can be severe and risk a host of negative consequences on quality of life. In fact, one survey among women found that 81% of those surveyed with stretch marks reported they were self-conscious about them, 69% were eager to have them gone, and 20% admitted they wouldn’t get intimate with partners with the lights on because of their stretch marks. Further, the survey notes that three out of every four women who are pregnant are actively attempting to prevent stretch marks, while 39% admit they immediately began to worry about and dread potential stretch marks once they discovered that they were pregnant. Many pregnant women reported being so concerned that 21% said they had greater anxiety over stretch marks than concerns with breastfeeding.
So, it’s clear that the demand for effective stretch mark reduction treatments is high, so how can your medical aesthetics clinic help?
Stretch marks start out as reddish lesions, called striae rubra, that can develop into more permanent, white lesions, called striae alba, over time. While stretch marks are the result of the progressive and often rapid stretching of the skin’s connective tissue, often associated with weight gain or growth in that area of the body, the precise cause is not well understood. Significant results have been reported using Venus Viva™, the industry’s most customizable skin resurfacing device powered by NanoFractional Radio Frequency (RF) with SmartScan™ technology that offers full operator control of ablation, coagulation, and resurfacing for optimal efficacy. Treatments are safe for all skin types with low downtime.
One published clinical study supports the effectiveness of Venus Viva™ in particular for treating stretch marks utilizing the NanoFractional RF™ applicator with SmartScan™ technology. In this study, patients with Fitzpatrick skin types III and IV presenting with striae alba on the thighs, abdomen, or buttocks received three Venus Viva™ treatments at four-week intervals. Four weeks after the final treatment, surface area, length, and width of the treated striae alba significantly decreased from the baseline (p < 0.001), with patient satisfaction scores regarding improvements in texture, size, and overall appearance reported at 96.67%, 93.94%, and 96.97%, respectively.
Satisfaction ratings from participating physicians reported a minimum 50% improvement in 69.7% of patients. Furthermore, the incidence of post-inflammatory hyperpigmentation (PIH) in this study was lower than that reported in studies using fractional CO2 lasers (81.2%) and fractional Erbium glass lasers (36.4%). Further, the significant induction of dermal collagen and elastin production was observed in all patients, concluding Venus Viva™’s NanoFractional RF™ technology is highly effective and recommended for the safe treatment of striae alba via skin resurfacing.
Interested in learning more about the technology behind this device or how to increase your practice revenue with Venus Viva™ for the treatment of stretch marks? Contact an expert today using the button below.
.png)
For more information call: (888) 907-0115 // info@venusconcept.com // 235 Yorkland Blvd., Suite 900, Toronto, ON, M2J 4Y8 Canada
REGULATORY CLEARANCES [ More ]
Venus Bliss™ is cleared by the FDA and licensed by Health Canada for non-invasive lipolysis of the abdomen and flanks in individuals with a Body Mass Index (BMI) of 30 or less, with the diode laser applicators. The (MP)2 applicator is cleared by the FDA for temporary reduction in the appearance of cellulite, and licensed by Health Canada for temporary increase of skin tightening, temporary circumferential reduction, and temporary cellulite reduction. Venus Bliss™ has CE Mark as a non-invasive medical aesthetic device enabling a comprehensive approach leading to body contouring, addressing fat reduction, skin tightening, circumference reduction, and cellulite reduction.
Venus Versa™ is cleared by the FDA, licensed by Health Canada, and has CE Mark as a multi-application device intended to be used in aesthetic and cosmetic procedures. The SR515 and SR580 applicators are cleared by the FDA, licensed by Health Canada, and have CE Mark for the treatment of benign pigmented epidermal and cutaneous lesions and treatment of benign cutaneous vascular lesions. The HR650/HR650XL and HR690/HR690XL applicators are cleared by the FDA, licensed by Health Canada, and have CE Mark for the removal of unwanted hair and to effect stable long-term or permanent hair reduction for Fitzpatrick skin types I-IV. The AC Dual applicator is cleared by the FDA, licensed by Health Canada, and has CE Mark for the treatment of acne vulgaris. The DiamondPolar™ and OctiPolar™ applicators on the Venus Versa™ system are cleared by the FDA for non-invasive treatment of moderate to severe facial wrinkles and rhytides on females with Fitzpatrick skin types I-IV. The DiamondPolar™ applicator is licensed by Health Canada and has CE Mark for non-invasive treatment of moderate to severe facial wrinkles and rhytides on females with Fitzpatrick skin types I-IV. The OctiPolar™ applicator on the Venus Versa™ system is licensed by Health Canada and has CE Mark for temporary body contouring via skin tightening, circumferential reduction, and cellulite reduction. The NanoFractional RF™ (Viva) applicator is cleared by the FDA, licensed by Health Canada, and has CE Mark for dermatological procedures requiring ablation and resurfacing of the skin.
ARTAS iX™ is cleared by the FDA, licensed by Health Canada and has CE Mark with indication for use for harvesting hair follicles from the scalp in men diagnosed with androgenic alopecia (male pattern hair loss) who have black or brown straight hair. ARTAS iX™ is intended to assist physicians in identifying and extracting hair follicular units from the scalp during hair transplantation; creating recipient sites; and implanting harvested hair follicles.
NeoGraft® is cleared by the FDA, licensed by Health Canada and has CE Mark with indication for use in suction-assisted follicular extraction and re-implantation. NeoGraft® is an auto-graft system and can be used on both male and female patients.
Venus Legacy™ is cleared by the FDA for the non-invasive treatment of moderate to severe facial wrinkles and rhytides in females with Fitzpatrick skin types I-IV with the OctiPolar™ and DiamondPolar™ applicators, and temporary reduction in the appearance of cellulite with the 4D Body (LB2) and 4D Face (LF2) applicators. It is licensed by Health Canada and has CE Mark for the temporary increase of skin tightening, temporary circumferential reduction, temporary cellulite reduction, and temporary wrinkle reduction.
Venus Velocity™ is cleared by the FDA, licensed by Health Canada and has CE Mark for hair removal, permanent hair reduction (defined as the long-term stable reduction in the number of hairs re-growing when measured at 6, 9 and 12 months after the completion of a treatment regimen), and the treatment of pseudofolliculitis barbae for all Fitzpatrick skin types.
Venus Fiore™ received regulatory approval in Israel for aesthetic and functional treatment of the vagina, labia and mons pubis. Venus Fiore™ is available for sale in India, Hong Kong, and other selected Asian countries.
The Venus Viva™ MD is cleared by the FDA, licensed by Health Canada and has CE Mark for the use in dermatological procedures requiring ablation and resurfacing of the skin using the Viva™/Viva™ MD applicator, and the non-invasive treatment, reduction in the appearance of moderate to severe facial wrinkles and rhytides for females in Fitzpatrick skin types I-IV with the DiamondPolar™ applicator.
The Venus Viva™ MD is cleared by the FDA for the use in dermatological procedures requiring ablation and resurfacing of the skin, and the non-invasive treatment of moderate to severe facial wrinkles and rhytides for females in Fitzpatrick skin types I-IV with the DiamondPolar™ applicator.
Venus Epileve™ is cleared by FDA, licensed by Health Canada and has CE Mark for hair removal, permanent hair reduction (defined as the long-term stable reduction in the number of hairs re-growing when measured at 6, 9 and 12 months after the completion of a treatment regimen), and the treatment of pseudofolliculitis barbae for all Fitzpatrick skin types. Venus Epileve™ is also CE-Marked for hirsutism.
Venus Freeze Plus™ is cleared by the FDA for the non-invasive treatment of moderate to severe facial wrinkles and rhytides in females with Fitzpatrick skin types I-IV. It is licensed by Health Canada for temporary skin tightening, and temporary reduction in the appearance of cellulite on the abdomen and flanks, using the DiamondPolar™ and OctiPolar™ applicators. The DiamondPolar™ applicator on Venus Freeze Plus™ has CE Mark for the non-invasive treatment of moderate to severe facial wrinkles and rhytides, and the increase of skin tightening, temporary circumferential reduction, and cellulite reduction with the OctiPolar™ applicator.
Venus Heal™ is licensed by Health Canada and can be used for the treatment of both acute and chronic disorders of the musculoskeletal system, such as muscle spasms, back pain, and soft tissue injuries, and results in effects such as pain relief, myorelaxation, increase of local blood circulation, and edema reduction. In the U.S., Venus Heal™ is cleared by the FDA for the relief of minor muscle aches and pain, relief of muscle spasm, and temporary improvement of local blood circulation. These indications enable the treatment of certain soft tissue injuries and conditions.
Venus Glow™ is cleared by the FDA as a Class I motorized dermabrasion device. It provides a dermal rejuvenation treatment that works to open up and deep-clean pores. Venus Concept is the exclusive distributor for Venus Glow™.
Venus Skin™ is a skin care line of various lotions and creams intended to improve different aspects of skin appearance, skin serums, and skin nourishment solutions.
Copyright 2023 Venus Concept. All rights reserved.
You are entering our website. For other countries/regions and language options, please click the SELECT A DIFFERENT REGION button below.
SELECT A DIFFERENT REGIONAre you looking to get a treatment? Please visit our patient website to learn more.
Click HereBe aware of schemes involving fraudulent job postings.
Read More